Christopher M Jones

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1724070/publications.pdf

Version: 2024-02-01

57 papers 6,082 citations

30 h-index 56 g-index

58 all docs 58 docs citations

58 times ranked 6008 citing authors

#	Article	IF	CITATIONS
1	Relationship between Nonmedical Prescription-Opioid Use and Heroin Use. New England Journal of Medicine, 2016, 374, 154-163.	13.9	902
2	Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health. Annals of Internal Medicine, 2017, 167, 293.	2.0	736
3	National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment. American Journal of Public Health, 2015, 105, e55-e63.	1.5	564
4	Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers – United States, 2002–2004 and 2008–2010. Drug and Alcohol Dependence, 2013, 132, 95-100.	1.6	434
5	Marijuana use and use disorders in adults in the USA, 2002–14: analysis of annual cross-sectional surveys. Lancet Psychiatry,the, 2016, 3, 954-964.	3.7	306
6	Changes in Synthetic Opioid Involvement in Drug Overdose Deaths in the United States, 2010-2016. JAMA - Journal of the American Medical Association, 2018, 319, 1819.	3.8	275
7	Co-occurring substance use and mental disorders among adults with opioid use disorder. Drug and Alcohol Dependence, 2019, 197, 78-82.	1.6	263
8	Vital Signs: Demographic and Substance Use Trends Among Heroin Users - United States, 2002-2013. Morbidity and Mortality Weekly Report, 2015, 64, 719-25.	9.0	262
9	What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose. Drug and Alcohol Dependence, 2014, 145, 34-47.	1.6	242
10	Sources of Prescription Opioid Pain Relievers by Frequency of Past-Year Nonmedical Use. JAMA Internal Medicine, 2014, 174, 802.	2.6	188
11	Patterns and Characteristics of Methamphetamine Use Among Adults — United States, 2015–2018. Morbidity and Mortality Weekly Report, 2020, 69, 317-323.	9.0	145
12	Prevalence and Correlates of Prescription Stimulant Use, Misuse, Use Disorders, and Motivations for Misuse Among Adults in the United States. American Journal of Psychiatry, 2018, 175, 741-755.	4.0	133
13	Prescription Opioid Misuse and Use of Alcohol and Other Substances Among High School Students — Youth Risk Behavior Survey, United States, 2019. MMWR Supplements, 2020, 69, 38-46.	15.3	133
14	Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder. Addiction, 2019, 114, 471-482.	1.7	114
15	Increases in methamphetamine use among heroin treatment admissions in the United States, 2008–17. Addiction, 2020, 115, 347-353.	1.7	104
16	The Evolving Overdose Epidemic: Synthetic Opioids and Rising Stimulant-Related Harms. Epidemiologic Reviews, 2020, 42, 154-166.	1.3	81
17	Resurgent Methamphetamine Use at Treatment Admission in the United States, 2008–2017. American Journal of Public Health, 2020, 110, 509-516.	1.5	75
18	Trends in and correlates of medical marijuana use among adults in the United States. Drug and Alcohol Dependence, 2018, 186, 120-129.	1.6	73

#	Article	IF	CITATIONS
19	Prescribing patterns of buprenorphine waivered physicians. Drug and Alcohol Dependence, 2017, 181, 213-218.	1.6	70
20	The paradox of decreasing nonmedical opioid analgesic use and increasing abuse or dependence — An assessment of demographic and substance use trends, United States, 2003–2014. Addictive Behaviors, 2017, 65, 229-235.	1.7	62
21	Targeting Youth to Prevent Later Substance Use Disorder: An Underutilized Response to the US Opioid Crisis. American Journal of Public Health, 2019, 109, S185-S189.	1.5	60
22	Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction. Annals of the New York Academy of Sciences, 2022, 1508, 3-22.	1.8	56
23	Frequency of Prescription Pain Reliever Nonmedical Use: 2002-2003 and 2009-2010. Archives of Internal Medicine, 2012, 172, 1265-7.	4.3	51
24	Evidence for state, community and systems-level prevention strategies to address the opioid crisis. Drug and Alcohol Dependence, 2019, 204, 107563.	1.6	50
25	Syringe services programs: An examination of legal, policy, and funding barriers in the midst of the evolving opioid crisis in the U.S International Journal of Drug Policy, 2019, 70, 22-32.	1.6	49
26	Time since first cannabis use and 12â€month prevalence of cannabis use disorder among youth and emerging adults in the United States. Addiction, 2019, 114, 698-707.	1.7	44
27	Epidemiology of the U.S. opioid crisis: the importance of the vector. Annals of the New York Academy of Sciences, 2019, 1451, 130-143.	1.8	41
28	Syringe Services Programs' Role in Ending the HIV Epidemic in the U.S.: Why We Cannot Do It Without Them. American Journal of Preventive Medicine, 2021, 61, S118-S129.	1.6	39
29	Trends in stimulant dispensing by age, sex, state of residence, and prescriber specialty — United States, 2014–2019. Drug and Alcohol Dependence, 2020, 217, 108297.	1.6	38
30	Associations of Parental Marijuana Use With Offspring Marijuana, Tobacco, and Alcohol Use and Opioid Misuse. JAMA Network Open, 2019, 2, e1916015.	2.8	36
31	Trends and key correlates of prescription opioid injection misuse in the United States. Addictive Behaviors, 2018, 78, 145-152.	1.7	34
32	Buprenorphine prescription dispensing rates and characteristics following federal changes in prescribing policy, 2017-2018: A cross-sectional study. Drug and Alcohol Dependence, 2020, 213, 108083.	1.6	34
33	Trends and correlates of cocaine use among adults in the United States, 2006–2019. Addictive Behaviors, 2021, 120, 106950.	1.7	32
34	Characteristics and current clinical practices of opioid treatment programs in the United States. Drug and Alcohol Dependence, 2019, 205, 107616.	1.6	31
35	Substance Use among Men Who Have Sex with Men. New England Journal of Medicine, 2021, 385, 352-356.	13.9	31
36	Comparing actual and forecasted numbers of unique patients dispensed select medications for opioid use disorder, opioid overdose reversal, and mental health, during the COVID-19 pandemic, United States, January 2019 to May 2020. Drug and Alcohol Dependence, 2021, 219, 108486.	1.6	30

#	Article	IF	CITATIONS
37	Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic. Drug and Alcohol Dependence, 2021, 225, 108783.	1.6	24
38	National Trends in and Correlates of Nonmedical Use of Prescription Stimulants, Nonmedical Use Frequency, and Use Disorders. Journal of Clinical Psychiatry, 2017, 78, e1250-e1258.	1.1	24
39	Prevalence and correlates of ever having a substance use problem and substance use recovery status among adults in the United States, 2018. Drug and Alcohol Dependence, 2020, 214, 108169.	1.6	23
40	Recent trends and associated factors of amphetamine-type stimulant overdoses in emergency departments. Drug and Alcohol Dependence, 2020, 216, 108323.	1.6	21
41	Primary care physicians' preparedness to treat opioid use disorder in the United States: A cross-sectional survey. Drug and Alcohol Dependence, 2021, 225, 108811.	1.6	20
42	Trends in and Characteristics of Buprenorphine Misuse Among Adults in the US. JAMA Network Open, 2021, 4, e2129409.	2.8	20
43	Cannabis Use and Cannabis Use Disorders Among Youth in the United States, 2002–2014. Journal of Clinical Psychiatry, 2017, 78, 1404-1413.	1.1	19
44	Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder?. Drug and Alcohol Dependence, 2021, 225, 108784.	1.6	18
45	Data quality considerations when using county-level opioid overdose death rates to inform policy and practice. Drug and Alcohol Dependence, 2019, 204, 107549.	1.6	16
46	Trends in the Nonmedical Use of OxyContin, United States, 2006 to 2013. Clinical Journal of Pain, 2017, 33, 452-461.	0.8	14
47	Adverse childhood experiences and stimulant use disorders among adults in the United States. Psychiatry Research, 2021, 299, 113870.	1.7	12
48	Characteristics of Adults Aged ≥18 Years Evaluated for Substance Use and Treatment Planning — United States, 2019. Morbidity and Mortality Weekly Report, 2022, 71, 749-756.	9.0	11
49	Characteristics of adults reporting illicitly manufactured fentanyl or heroin use or prescription opioid misuse in the United States, 2019. Drug and Alcohol Dependence, 2021, 229, 109160.	1.6	7
50	Characterizing and Identifying the Prevalence of Web-Based Misinformation Relating to Medication for Opioid Use Disorder: Machine Learning Approach. Journal of Medical Internet Research, 2021, 23, e30753.	2.1	7
51	Reprint of Trends and key correlates of prescription opioid injection misuse in the United States. Addictive Behaviors, 2018, 86, 24-31.	1.7	5
52	Reducing negative consequences from use of methamphetamine. Addiction, 2020, 115, 1190-1191.	1.7	5
53	Evaluating opioid analgesic prescribing limits: A narrative review. Pharmacoepidemiology and Drug Safety, 2022, 31, 605-613.	0.9	5
54	Exponential increases in drug overdose: Implications for epidemiology and research. International Journal of Drug Policy, 2022, 104, 103676.	1.6	5

#	Article	IF	CITATIONS
55	Signals of increasing co-use of stimulants and opioids from online drug forum data. Harm Reduction Journal, 2022, 19, .	1.3	5
56	County-level sociodemographic differences in availability of two medications for opioid use disorder: United States, 2019. Drug and Alcohol Dependence, 2022, 236, 109495.	1.6	3
57	Commentary on Chan & Hall (2020): Advances in specifying cannabis consumption. Addiction, 2020, 115, 1187-1188.	1.7	0